Abstract
Cannabinoid receptor agonist 13 (CRA13) is a novel cannabinoid (CB) receptor agonist with high affinity and functional activity toward both CB1 and CB2 receptors. This phase I study aimed to evaluate the pharmacokinetics, safety, and tolerability of single oral doses of CRA13. Sixty-three of 69 healthy adult males were randomized in seven cohorts (n = 9) to receive 1 to 80 mg of CRA13 or placebo orally in fasted condition. To investigate the diet effect, an independent group (n = 6) was randomized to receive 40 mg of CRA13 after high-fat and high-calorie breakfast in crossover design with a 2-week washout period. Peak plasma concentration (Cmax) ranged from 7.8 to 467.6 ng/ml (1–80 mg). CRA13 was rapidly absorbed and demonstrated linear pharmacokinetics (1–80 mg). Time to reach Cmax (tmax) was 1.5 to 2 h for all doses in both fasted and fed groups. Administration of 40 mg of CRA13 with food induced approximately 2-fold increase in the Cmax and the area under the concentration-time curve, AUC0 – tz. The apparent elimination half-life (t1/2) was 21 to 36 h and 30 to 41 h for fasted and fed groups, respectively. Dizziness, headache, and nausea were the most frequently reported adverse events (AEs), predominantly at the 40- and 80-mg doses. The incidence of AEs was dose-dependent and mild to moderate. No deaths and serious adverse events were reported. In conclusion, CRA13 was reasonably well tolerated and demonstrated a linear pharmacokinetics over the studied dose range (1–80 mg). Food intake increased CRA13 Cmax and AUC0 – tz by approximately 2-fold, whereas tmax was unaffected.
Footnotes
-
This work was supported by Novartis Pharma AG.
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.108.024000.
-
ABBREVIATIONS: CRA13, cannabinoid receptor agonist 13; CB, cannabinoid; CNS, central nervous system; ECG, electrocardiogram; AE, adverse event; LLOQ, lower limit of quantification; Cmax, plasma concentration; tmax, time to reach Cmax; AUC, area under the curve; CI, confidence interval; CV, coefficient(s) of variation; log P, log partition coefficient.
- Received September 19, 2008.
- Accepted January 13, 2009.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|